Pharmacy stop-smoking service expands to ‘non-registered’ staff

The new pharmacy contract has expanded who can deliver the smoking cessation service, as well as adding the provision of two drugs via PGDs.

CPE will announce when the changes will come into force “in due course”

The pharmacy smoking cessation service has been expanded to “enable better use of skill mix” with delivery of “parts” of the service by “registered and non-registered pharmacy staff”, the government announced this week (March 31).

Under the new pharmacy contract for 2025/26, “suitably trained and competent staff” who are not pharmacists or pharmacy technicians can deliver consultations for the service, Community Pharmacy England (CPE) said.

Read more: Funding breakdown: Write-offs, service payments and activity fees

The reforms also include the introduction of patient group directions (PGDs) for the provision of varenicline and cytisinicline (cytisine) under the service, which can be delivered by both pharmacy technicians and pharmacists, CPE added.

The negotiator set out that these changes “will require developments to IT systems” and the date they will apply from “will be announced in due course”.

Read more: ‘Don’t sign up!‘: LPC chief advises against new smoking service over fees and safety concerns

Other services expanded as part of the new deal this week include the pharmacy contraception service (PCS), with the morning-after pill to be made “available free of charge” at pharmacies in England from October.

Antidepressants will also be added to the new medicine service (NMS) from October, while £215 million will fund the cost of Pharmacy First clinical pathways consultations as well as the PCS and the hypertension case-finding service (HCFS).

And CPE announced a raft of increases in fees for various services, as well as a delay to the “bundling” requirement for pharmacies to offer the PCS, HCFS and Pharmacy First to qualify for a monthly fixed payment.

Vape “starter kit”

It comes after a local pharmaceutical committee (LPC) advised contractors in February “not to sign up” to a new smoking cessation service agreement over “unacceptable” fees that meant pharmacies engaging with it would be “doing so at a loss”.

In January, MPs called for clarifications of advertising restrictions for nicotine vapes to ensure pharmacists don’t find themselves “on the wrong side of the law” for promoting vaping as a “stop smoking device”.

Read more: MPs: Pharmacists must not be ‘criminalised’ over vapes as quit aid

CPE announced in November that pilot pharmacies were set to offer patients vouchers for a vape “starter kit” and “up to four weeks’ worth of vape liquid” in a bid to help them stop smoking.

And last April, data from NHS Stop Smoking Services in England showed a 10% rise in the number of people using community pharmacies to start quitting smoking.

Check the C+D site for the latest coverage on this developing story

Sign in or register for free

Latest from Clinical

DH to place ‘explicit restrictions’ on funded blood pressure checks

  • comment

The pharmacy hypertension service specification is set to be updated to exclude patients who request “frequent measurement of their blood pressure”.

NHSE mulls pharmacy HPV vaccine rollout

 
• By 
 • comment

NHS England (NHSE) has suggested that community pharmacies should offer HPV vaccinations to “raise awareness” and increase uptake of the jab.

Pharmacy stop-smoking service expands to ‘non-registered’ staff

 
• By 
 • comment

The new pharmacy contract has expanded who can deliver the smoking cessation service, as well as adding the provision of two drugs via PGDs.

More from Funding

exclusive

CPE: Almost half of £645m recovery plan funds unspent

 
• By 
 • comment0

The pharmacy negotiator estimates some £296m of remaining primary care recovery plan funding “will have been used by NHS England (NHSE) in other ways”, C+D has learned.

All the headlines: Community pharmacy funding deal

 
• By 
 • comment0

Find out everything you need to know about the government’s plans for community pharmacy – as outlined in this week’s long-awaited pharmacy funding deal.